IL17A and gastric cancer: In patients with gastric cancer at stages I, II, and III of the disease, there is an increase in such proinflammatory cytokines as TNF-α, IL-2, IL-8, TNF-β, IL-17A, and IL-6, as well as a decrease in IFNγ.